$2995 | Single User
$4495 | Multi User
$8995 | Site License
$14995 | Global License

Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 [Report Updated: 01-10-2017]

Published by Current Partnering: 01 Oct 2017 | 119442 | In Stock

Introduction

The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2017 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of over 2,000 clinical stage partnering deals announced since 2010 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.


The initial chapters of this report provide an orientation of clinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner clinical stage compounds/products.


Chapter 3 provides an overview of clinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in clinical stage deals.


Chapter 5 provides a review of clinical stage deal making since 2010. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.


Chapter 6 provides a detailed analysis of clinical stage payment terms including headline, upfront, milestone and royalty rates for phase I, phase II and phase III deals.


Chapter 7 provides a review of the leading clinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.


Chapter 8 provides a comprehensive listing of the top 50 most active clinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.


Chapter 9 provides a comprehensive and detailed review of clinical stage partnering deals signed and announced since 2010, where a contract document is available in the public domain.


Chapter 10 provides a comprehensive directory of clinical stage partnering deals since 2010 organized by stage of development – phase I, phase II and phase III.


The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.


The report also includes numerous tables and figures that illustrate the trends and activities in clinical stage partnering and deal making since 2010.


In addition, a comprehensive appendix of all clinical stage deals since 2010 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of clinical stage products and compounds.


Key benefits


Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2017 provides the reader with the following key benefits:


In-depth understanding of clinical stage deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of clinical stage agreements with numerous real life case studies

Insight into the terms included in a clinical stage agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2017 is intended to provide the reader with an in-depth understanding and access to clinical stage deal trends and structure of deals entered into by leading companies worldwide.


Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2017 includes:


Trends in clinical stage dealmaking in the biopharma industry since 2010

Analysis of clinical stage deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life clinical stage deals

Access to over 2,000 clinical stage deals

The leading clinical stage deals by value since 2010

Most active clinical stage dealmakers since 2010

The leading clinical stage partnering resources


In Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2017, the available contracts are listed by:


Company A-Z

Headline value

Stage of development at signing

Deal type

Specific therapy target


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2017 report provides comprehensive access to available deals and contract documents for over 2,000 clinical stage deals. Analyzing actual contract agreements allows assessment of the following:


What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Table of Contents
for Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 [Report Updated: 01-10-2017]

  • Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Why do companies partner clinical stage compounds?

    2.1. Introduction

    2.2. The role of clinical stage partnering

    2.2.1. In-licensing at clinical stage

    2.2.2. Out-licensing at clinical stage

    2.3. Difference between phase I, II and III stage deals

    2.4. Reasons for entering into clinical stage partnering deals

    2.4.1. Licensors reasons for entering clinical stage deals

    2.4.2. Licensees reasons for entering clinical stage deals

    2.5. The future of clinical stage partnering deals

    Chapter 3 – Clinical stage deal strategies and structure

    3.1. Introduction

    3.2. At what stage do companies partner?

    3.2.1. Partnering early in pharmaceutical/biotech

    3.2.1.1. Discovery and preclinical stage partnering case studies

    3.2.1.1.a. Case study: LEO Pharma - 4SC

    3.2.1.1.b. Case study: Heptares Therapeutics - Cubist

    3.2.1.1.c. Case study: Incyte – Agenus Bio

    3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec

    3.2.2. Partnering later in pharmaceutical/biotech

    3.2.2.1. Clinical stage partnering case studies

    3.2.2.1.a. Case study: Servier – GeNeuro

    3.2.2.1.b. Case study: Teva – Xenon Pharmaceuticals

    3.2.2.1.c. Case study: AstraZeneca - Ardelyx

    3.2.2.1.d. Case study: Baxter – Onconova Therapeutics

    3.3. Early and later stage partnering – a risk/cost comparison

    3.4. What do companies spend on clinical stage partnering?

    3.5. Pure versus multi-component partnering deals

    3.6. Pure licensing agreement structure

    3.6.1. Example pure licensing agreements

    3.6.1.a. Case study : Argos Therapeutics – Medinet

    3.6.1.b. Case study : Pfizer - GlycoMimetics

    3.7. Multicomponent clinical stage partnering agreements

    3.7.1. Example multicomponent clinical stage clauses

    3.7.1.a. Case study: Gilead Sciences – GlobeImmune

    Chapter 4 – Clinical stage partnering payment strategies

    4.1. Introduction

    4.2. Clinical stage payment strategies

    4.3. Payment options

    4.3.1. Headline values

    4.3.2. Upfront payments

    4.3.2.1. Conditionality of upfront payments

    4.3.3. Loans

    4.3.4. Convertible loans

    4.3.5. Equity

    4.3.6. R&D funding

    4.3.7. Licensing fees

    4.3.8. Milestone payments

    4.3.9. Royalty payments

    4.3.9.1. Issues affecting royalty rates

    4.3.9.2. Royalties on combination products

    4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech

    4.3.9.3. Guaranteed minimum/maximum annual payments

    4.3.9.4. Royalty stacking

    4.3.9.5. Royalties and supply/purchase contracts

    4.3.10. Quids

    4.3.11. Option payments

    Chapter 5 – Trends in clinical stage deal making

    5.1. Introduction

    5.2. Clinical stage partnering over the years

    5.2.1. Trends in phase I deals since 2010

    5.2.1.1. Attributes of phase I deals

    5.2.2. Trends in phase II deals since 2010

    5.2.2.2. Attributes of phase II deals

    5.2.3. Trends in phase III deals since 2010

    5.2.3.1. Attributes of phase III deals

    5.3. Clinical stage partnering by deal type

    5.4. Clinical stage partnering by disease type

    5.5. Partnering by clinical stage technology type

    5.6. Clinical stage partnering by most active company since 2010

    Chapter 6 – Payment terms for clinical stage partnering

    6.1. Introduction

    6.2. Guidelines for clinical stage payment terms

    6.2.1. Upfront payments

    6.2.2. Milestone payments

    6.2.3. Royalty payments

    6.3. Clinical stage payment terms – deal data analysis

    6.3.1. Public data

    6.3.2. Survey data

    6.4. Payment terms analysis

    6.4.1. Clinical stage partnering headline values

    6.4.2. Clinical stage deal upfront payments

    6.4.3. Clinical stage deal milestone payments

    6.4.4. Clinical stage royalty rates

    6.5 Clinical stage median financials

    6.5.1. Clinical stage headline value

    6.5.2. Clinical stage upfront value

    6.5.3. Clinical stage milestone value

    6.5.4. Clinical stage royalty value

    Chapter 7 – Leading clinical stage deals

    7.1. Introduction

    7.2. Top clinical stage deals by value

    Chapter 8 – Top 50 most active clinical stage dealmakers

    8.1. Introduction

    8.2. Top 50 most active clinical stage dealmakers

    Chapter 9 – Clinical stage partnering contracts directory

    9.1. Introduction

    9.2. Clinical stage deals with contracts since 2010

    Chapter 10 – Clinical stage deal making by development stage

    10.1. Introduction

    10.2. Deals by clinical stage

    Phase I

    Phase II

    Phase III

    Regulatory

    Formulation

    Appendices

    Appendix 1 – Clinical stage dealmaking by companies A-Z

    Appendix 2 – Clinical stage dealmaking by industry sector

    Appendix 3 – Clinical stage dealmaking by stage of development

    Appendix 4 – Clinical stage dealmaking by therapy area

    Appendix 5 – Clinical stage dealmaking by technology type

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent report titles from Current Partnering

    Table of figures

    Figure 1: Definition of clinical phases in dealmaking

    Figure 2: Agreements signed by phase of development (2010- 2017), % of all deals

    Figure 3: Components of the pure licensing deal structure

    Figure 4: Payment options for clinical stage partnering deals

    Figure 5: Issues affecting royalty rates

    Figure 6: Clinical stage partnering frequency since 2010

    Figure 7: Phase I clinical stage partnering since 2010

    Figure 8: Phase II clinical stage partnering since 2010

    Figure 9: Phase III clinical stage partnering since 2010

    Figure 10: Clinical stage partnering by deal type since 2010

    Figure 11: Clinical stage partnering by disease type since 2010

    Figure 12: Clinical stage partnering by technology type since 2010

    Figure 13: Top 50 most active clinical stage dealmakers since 2010

    Figure 14: Review of upfront payments for clinical stage deals

    Figure 15: Review of milestone payments for clinical stage deals

    Figure 16: Review of royalty payments for clinical stage deals

    Figure 17: Clinical stage deals with a headline value

    Figure 18: Clinical stage deals with an upfront value

    Figure 19: Clinical stage deals with a milestone value

    Figure 20: Clinical stage deals with a royalty rate value

    Figure 21: Summary median headline value by clinical stage of development since 2010

    Figure 22: Summary median upfront payments by clinical stage of development since 2010

    Figure 23: Summary median milestone payments by stage of development since 2010

    Figure 24: Summary median royalty rate by stage of development since 2010

    Figure 25: Top clinical stage deals by value since 2010

    Figure 26: Most active clinical stage dealmakers since 2010

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

119442 | CP2058

Number of Pages

1000

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016
The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016 report pr...
01 Oct 2016 by Current Partnering USD $2,995 More Info
Sogo Clinical Holdings Co., Ltd. (2399) - Financial and Strategic SWOT Analysis Review
SummarySogo Clinical Holdings Co., Ltd. (Sogo) is a site management organization that provides suppo...
09 Jan 2016 by Global Data USD $300 More Info
Sapporo Clinical Laboratory Inc. (9776) - Financial and Strategic SWOT Analysis Review
SummarySapporo Clinical Laboratory Inc. (Sapporo) is a clinical laboratory testing service provider ...
09 Jan 2016 by Global Data USD $300 More Info
Sogo Clinical Holdings Co., Ltd. (2399) - Financial and Strategic SWOT Analysis Review
SummarySogo Clinical Holdings Co., Ltd. (Sogo) is a site management organization. The company provid...
08 Nov 2015 by Global Data USD $300 More Info
Sapporo Clinical Laboratory Inc. (9776) - Financial and Strategic SWOT Analysis Review
SummarySapporo Clinical Laboratory Inc. (Sapporo) is a clinical laboratory testing service provider ...
08 Nov 2015 by Global Data USD $300 More Info
Enzo Clinical Labs, Inc. - Medical Equipment - Deals and Alliances Profile
SummaryEnzo Clinical Labs, Inc. (Enzo Clinical), a subsidiary of Enzo Biochem, Inc. is a clinical re...
16 Oct 2015 by Global Data USD $250 More Info
Clinical Trial Design for Commercial Success
IntroductionClinical Trial Design for Commercial Success offers expert insights on how to best posit...
01 Jun 2015 by FirstWord Pharma USD $695 More Info
Designing Clinical Trials to Show Value
IntroductionOnce, they were the benchmark for product development. But these days, randomised contro...
01 Jan 2014 by FirstWord Pharma USD $695 More Info
The Path to Product Inclusion in Clinical Guidelines: Strategies for Success
IntroductionClinical guidelines are taking hold in the practice of medicine. Though not always volun...
01 Feb 2013 by FirstWord Pharma USD $695 More Info
Tapping Social Media for Clinical Trial Recruitment
IntroductionWith an estimated 80% of all clinical trials failing to achieve enrolment goals, sponsor...
01 Apr 2012 by FirstWord Pharma USD $695 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 [Report Updated: 01-10-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data